EC Number |
Inhibitors |
Structure |
---|
2.7.7.6 | (NH4)2SO4 |
- |
|
2.7.7.6 | (S)-2-((1-amino-1-oxo-3-phenylpropan-2-ylamino)methyl)-3-(4-amino phenoxy)-5-methoxy phenyl acetate |
- |
|
2.7.7.6 | (S)-2-((1-amino-1-oxo-3-phenylpropan-2-ylamino)methyl)-5-methoxy-3-(4-nitrophenoxy)phenyl acetate |
- |
|
2.7.7.6 | (S)-2-((1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-ylamino)methyl)-3-(4-aminophenoxy)-5-methoxyphenyl acetate |
- |
|
2.7.7.6 | (S)-2-((1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-ylamino)methyl)-5-methoxy-3-(4-nitrophenoxy)phenyl acetate |
- |
|
2.7.7.6 | 1,3-dimethoxy-5-(4-nitrophenoxy) benzene |
- |
|
2.7.7.6 | 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine |
i.e. ECyd, TAS-106, a antitumor ribonucleoside that inhibits RNA polymerase, acts synergistically in inhibiting A-549 cancer cell growth and in tumor growth in vivo. The compound also inhibits the checkpoint-associated protein, the expression of Chk1 protein and the phosphorylation of Chk1 and Chk2, antitumour effects in combination with cisplatin, overview |
|
2.7.7.6 | 1-[2-[3-(4-Chloro-3-trifluoromethylphenyl)ureido]-4-trifluoromethyl phenoxy]-4,5-dichlorobenzene sulfonic acid |
- |
|
2.7.7.6 | 2'-C-ethynyl-7-deaza-ATP |
causes immediate chain termination |
|
2.7.7.6 | 2'-C-Me-ATP |
causes immediate chain termination |
|